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Background: To compare the effect of bimatoprost and the fixed combination latanoprost-timolol (LTFC) on 24-hour
systolic (SBP) and diastolic (DBP) blood pressure and on 24-hour ocular perfusion pressure (OPP).
Methods: 200 patients with glaucoma or ocular hypertension, controlled on the unfixed combination of latanoprost
and timolol or eligible for dual therapy being not being fully controlled on monotherapy were enrolled in a
randomized, double-masked, placebo-controlled, multicentre clinical trial. They were randomized to LTFC (8 a.m.)
or bimatoprost (8 p.m.) and received 24-hour IOP curve at baseline, 6 and 12 weeks (supine and sitting position
IOPs were recorded at 8 p.m., midnight, 5 a.m., 8a.m., noon and 4 p.m.). Holter 24-hour blood pressure curve was
obtained between weeks 2 and 12. SBP, DBP, OPP were calculated and compared with ANOVA. Rates of diastolic
OPP (DPP) ≤50, ≤40, ≤30 mmHg in the 2 groups were calculated and compared using Fisher’s test.
Results: Mean baseline SBP and DBP were 136.5 ± 18.3 vs 134.2 ± 20.1 mmHg (p = 0.1) and 79.1 ± 10.2 vs 78.2 ± 10.1
mmHg (p = 0.4) in the bimatoprost and LTFC groups respectively. Holter SBP was significantly higher for bimatoprost
(135.1 mmHg vs 128.1 mmHg, p = 0.04), while no statistically significant difference in DBP was found. DPP was similar in
the 2 groups, and proportions of patients with at least one value of the 24-hour curve ≤50, ≤40, ≤30 mmHg were 94%,
86%, 41% respectively.
Conclusions: Bimatoprost and LTFC had similar DBPs and OPPs; SBP was significantly lower with LTFC. In this study,
the percentage of “dippers” was considerably higher than the one described in previous studies on the role of
perfusion pressure in glaucoma.
Trial registration: NCT02154217, May 21, 2014.Background
Primary open angle glaucoma (POAG) is a disease whose
pathogenesis is not completely clear [1]. There is evidence
that elevated intraocular pressure (IOP) is a strong risk
factor for both occurrence and progression of glaucoma
[2,3] and also that IOP reduction can be highly protective
from worsening of the disease [4]. However, IOP alone
can hardly explain all of the pathogenesis of glaucoma and* Correspondence: luca.rossetti@unimi.it
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unless otherwise stated.the importance of vascular factors, in particular of perfu-
sion pressure (PP), has been ascertained in a number of
epidemiologic studies and clinical trials as well [5-8]. Low
values of diastolic perfusion pressure (DPP) have been
reported to be a major risk factor for the incidence of
glaucoma [9,10], and a decreased DPP was found to be
a significant predictor for glaucoma progression [11-13].
Yet, the “independent” role of PP in the pathogenesis of
the disease is debated [14]; a further issue is the way PP is
calculated and assessed in multivariate analyses together
with IOP [15]. Evaluation of both IOP and PP is often a
critical point in the context of an epidemiologic study andl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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considerably vary during the 24-hour and can be sus-
ceptible to a number of other variables (time point of
the day or night, concomitant use of systemic or local
drugs, emotional stress during the measurement, etc.).
Probably the best way to evaluate IOP rhythm is by
means of 24-hour measurements [16-20], while the
24-hour Holter recording is the most appropriate pro-
cedure to get an estimate of the systemic blood pressure
during a 24-hour period.
The effect of beta-blockers and prostaglandin analogues
on IOP reduction is well known [21], whereas these drugs’
effect on PP has been studied only more recently [22,23].
A European multicenter randomized clinical trial was con-
ducted with the aim of comparing the effectiveness and
safety of bimatoprost and of the LTFC in lowering IOP
in patients with POAG or OH when switched from a
non-fixed combination of latanoprost and timolol, and
the findings have been published [24]. The objective of
this paper was to investigate the effect of these drugs
on PP, assess the number of patients “at risk” due to low
DPP despite apparently good IOP control and to calculate
the proportion of time in a day when patients were, on
average, below PP values that we conventionally consider
as “potentially safe”.
Methods
The study was carried out at 7 European University Eye
Clinics after the approval of the Ethics Committee of
the Universities of Milan, Rome, Bari (Italy), Larissa,
Thessaloniki (Greece), Dresden, Magdeburg (Germany),
Basel (Switzerland). All patients signed a written informed
consent form. The patients and the methods of this trial
have been described in a previous paper [24]; in this paper,
we described in detail the methods for evaluation of IOP
and blood pressure and their analyses. Patients’ inclusion
criteria were the following:
Inclusion criteria:
– POAG/PEX or OH patients aged 18 years or more
– patients controlled (IOP <21 mmHg) on the unfixed
combination of latanoprost and timolol for at least 3
months prior to the baseline visit.
– patients on monotherapy either with latanoprost or
timolol eligible for dual therapy (IOP >21 mmHg, or
target IOP not reached).
Exclusion criteria:
– contraindications to beta-blockers
– closed/barely open anterior chamber angles or
history of acute angle closure.
– ocular surgery or argon laser trabeculoplasty within
the last 3 months.– ocular inflammation/infection occurring within 3
months prior to pre-trial visit.
– neovascular glaucomas.
– hypersensitivity to benzalkonium chloride or to any
other component of the trial drug solutions.
– other abnormal ocular condition or symptom
preventing the patient from entering the trial.
– patients on either bimatoprost or the LTFC
– patients who had undergone refractive surgery
– inability to adhere to treatment/visit plan.
– participation in any other clinical trial (i.e., requiring
informed consent) within one month prior to pre-study
visit.
– pregnancy, nursing, or, if applicable, not using
adequate contraception.
– any drug known to affect IOP.Study design
This was a 12-week, multicentre, randomized, double-
masked study. The trial was conducted in accordance
with the ethical principles that have their origins in the
Declaration of Helsinki and its amendment of October
2000 (Edinburgh, Scotland), the European Guidelines
on Good Clinical Practice (GCP) and the International
Conference on Harmonisation (ICH) Guidelines. The
trial included five visits: 1) patients were checked for
eligibility at the pre-trial screening visit; if potentially
eligible, only patients on monotherapy started wash-in
medications (unfixed combination of latanoprost and
timolol) after the screening visit; 2) baseline visit after
at least 6 weeks of wash-in; 3) week 2 visit (safety visit
including biomicroscopy, single IOP measurement and
evaluation of adverse events); 4) week 6 visit; 5) week
12 visit. At the end of the study (3 weeks after week 12
visit) a safety visit was optional.
The baseline visit and the week 6 and 12 visits re-
quired hospitalization and patients were evaluated for 24
hours. Patients were hospitalized at 7 pm to undergo a
24-hour IOP assessment. Supine and sitting position IOP
was measured at 8 pm, midnight, 5 am, 8 am, noon, and
4 pm; 15 minutes around the time point were allowed. At
8 pm and at 8 am, the study drops were administered by
the study personnel. Both 8 a.m. and 8 p.m. tonometric
recordings were performed before study drugs were ad-
ministered. Supine IOP was measured using the hand-
held Perkins tonometer with the patient resting on a
bed for at least 10–15 minutes. Sitting IOP was measured
with the Goldmann applanation tonometer. At each time
point IOP was measured twice, and then averaged. If the 2
recordings were not within 2 mmHg a third measurement
was taken and the average calculated. All assessments
were performed by the same well-trained evaluators differ-
ent from the study personnel administrating the drugs.
Table 1 Patients’ main characteristics
Bimatoprost LTFC
Total 101 99
Age, mean (sd) 64.7 (11.5) 67.8 (10.8)
Male (%) 55 (54.5) 53 (53.5)
POAG/PEX (%) 78 (77) 80 (81)
OH (%) 23 (23) 19 (19)
MD, mean (sd) −4.2 (2.3 dB) −4.6 (2.7 dB)
CCT, mean (sd) 543 (38 μm) 535 (39 μm)
Systemic Drugs
Antihypertensives (%) 42 (41) 40 (40)
Antidepressants (%) 6 (6) 8 (8)
Hypoglycemics oral (%) 11 (11) 13 (13)
Cholesterol-lowering drugs (%) 13 (13) 15 (15)
Antiarrhythmics (%) 5 (5) 4 (4)
LTFC: latanoprost/timolol fixed combination; sd: standard deviation; POAG:
primary open-angle glaucoma; PEX pseudoexfoliative glaucoma; OH: ocular
hypertension; MD: mean deviation; CCT: central corneal thickness.
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Holter 24-hour blood pressure recording not earlier
than 2 weeks after having started the trial medications.
Study treatments
Patients on monotherapy (either latanoprost or timolol)
underwent a wash-in phase lasting 6 weeks. Wash-in treat-
ment consisted in timolol (Timolol XE morning adminis-
tration) and latanoprost (Xalatan evening administration).
After baseline 24-hour evaluation, each patient was allo-
cated to one of the two treatment groups according to a
centralized computer-generated randomisation code list
prepared and kept at each institute by an independent
administrator: 1) LTFC (Xalacom) at 8 am + placebo at
8 pm; 2) placebo at 8 am+ bimatoprost (Lumigan) at 8 pm.
Identical bottles were used for masking purposes.
Definitions
The nocturnal period was from 11 pm to 7 am. Perfu-
sion pressure was calculated as blood pressure (systolic,
diastolic) minus IOP (taken from the habitual body pos-
ition readings). During the Holter acquisition, blood pres-
sure was measured every 15 minutes as opposite to IOP,
which was measured every 4 hours. For the aims of the
study, it was important to consider values which were
less affected as possible by disturbing factors (such as
sudden awakening, change in body position, exposure
to light etc.).
In order to use all available BP readings (ideally 96 per
patient), we arbitrarily calculated perfusion pressure by
subtracting the closest IOP reading to BP. For sake of
clarity, considering the period from 10:00 pm to 9:59 am,
perfusion pressures for BP collected between 10:00 pm
and 1:59 am were calculated using the midnight IOP
measurement; from 2:00 am to 5:59, the 4 am IOP reading
was subtracted to the singles BP readings, whereas from
6:00 to to 9:59 am, the 8 am IOP reading was used.
Statistical analysis
Comparisons between treatments and within the 2 treat-
ment groups with baseline were carried out with ANOVA.
The following parameters were compared: a. IOP at base-
line, at week 6 and week 12; b. IOP difference between
baseline and week 12; c. 24-hour diastolic blood pressure
(DBP), 24-hour systolic blood pressure (SBP) at the time
of Holter acquisition; 24-hour DPP, 24-hour SPP at the
time of Holter acquisition; nocturnal DPP, nocturnal SPP
at the time of Holter acquisition.
The study population (as a whole and for subgroups)
was also stratified based on the mean nocturnal DPP
(using cut-off values of ≤50, ≤45, ≤40, ≤35, ≤30 mmHg).
For each cut-off value, mean nocturnal DPP were calcu-
lated and compared. Rates of DPP ≤50, ≤45, ≤40, ≤35, ≤30
mmHg in the 2 groups were calculated and comparedusing Fisher’s test. In addition, the proportion of time
in the day when DPP was below a given cut-off value
was calculated.
The details of sample size calculation are reported in
another paper [24] and were based on the 24-hour mean
change in IOP. In the estimates below, the significance
level was set to 5% and the power to 80%. The numbers
of 81 patients per group (1-sided test) and 102 patients per
group (2-sided test) were calculated for a delta of 1.5 mmHg
and a standard deviation of 3.8 mmHg. P-values were
adjusted for multiple comparisons (Bonferroni corrections).
Results
A total of 200 patients were enrolled in the trial. All pa-
tients completed the study. A protocol violation occurred
for two patients: one was treated for a bacterial conjunc-
tivitis and another started a therapy with a systemic beta-
blocker during the study. All data presented in the paper
refer to the intention-to-treat analysis. Per-protocol ana-
lysis showed very similar results. Patients’ main character-
istics are shown in Table 1. The majority of patients had
initial to moderate glaucoma and about 20% of cases had
OH. Treatment for systemic hypertension was common
and 40% of the whole sample was taking an antihyperten-
sive drug.
Results about IOP and PP are reported in Table 2.
Very similar IOP levels at baseline and at 12 weeks were
found in the 2 groups and no statistically significant
difference was shown at any comparison. Baseline (i.e.
under the unfixed combination of latanoprost and timolol)
mean IOP was 16.3 mmHg (3.3) vs 15.5 mmHg (2.9) in
bimatoprost and LTFC groups respectively and similar
figures were shown when nocturnal IOPs were analyzed.
Table 2 Comparison of intraocular, systemic and
perfusion pressures (mmHg) in the 2 groups
Bimatoprost LTFC p-value
Baseline IOP (sd) 16.3 (3.3) 15.5 (2.9) 0.2
Baseline nocturnal IOP (sd) 16.9 (3.6) 16.0 (3.3) 0.3
Baseline SBP (sd) 136.5 (18.3) 134.2 (20.1) 0.1
Baseline DBP (sd) 79.1 (10.2) 78.2 (10.1) 0.4
Baseline nocturnal SBP (sd) 121.0 (13.8) 122.1 (15.8) 0.3
Baseline nocturnal DBP (sd) 72.7 (7.9) 73.2 (9.5) 0.4
Baseline SPP (sd) 120.2 (15.7) 118.7 (16.8) 0.3
Baseline DPP (sd) 62.8 (6.9) 62.7 (8.2) 0.6
Baseline nocturnal SPP (sd) 104.1 (13.1) 106.1 (16.4) 0.2
Baseline nocturnal DPP (sd) 55.8 (8.0) 57.2 (12.1) 0.1
12 week IOP (sd) 16.1 (2.5) 16.3 (3.7) 0.7
12 week nocturnal IOP (sd) 16.1 (2.6) 16.1 (3.9) 0.8
Holter SBP (sd) 135.1 (16.7) 128.1 (15.3) 0.04
Holter DBP (sd) 79.5 (8.3) 78.7 (11.8) 0.4
Holter nocturnal SBP (sd) 124.8 (14.4) 120.0 (14.5) 0.08
Holter nocturnal DBP (sd) 71.7 (7.9) 70.6 (11.3) 0.2
Holter SPP (sd) 119.0 (10.8) 111.8 (15.3) 0.03
Holter DPP (sd) 63.4 (8.0) 62.4 (11.1) 0.1
Holter nocturnal SPP (sd) 108.7 (14.4) 103.9 (17.3) 0.07
Holter nocturnal DPP (sd) 55.6 (7.4) 54.5 (12.3) 0.2
LTFC: latanoprost/timolol fixed combination; IOP: intraocular pressure; sd:
standard deviation; SBP: systolic blood pressure; DBP: diastolic blood pressure;
SPP: systolic perfusion pressure; DPP: diastolic perfusion pressure.
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groups and, as expected, were significantly lower during
the night (p = 0.01). There was no statistically significant
difference between the study drugs for all comparisons
but for Holter SBP and SPP that were significantly higher0
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Figure 1 Percentage of patients showing at least 1 DPP below the givin the group treated with bimatoprost (135.1 mmHg vs
128.1 mmHg and 119.0 mmHg vs 111.8 mmHg in bimato-
prost and LTFC groups respectively, p = 0.04, p = 0.03).
Figure 1 is showing the proportion of patients who had
at least 1 DPP reading below a given cut-off value. More
than 90% of the patients had at least one DPP measure-
ment below 50 mmHg, more than 80% below 40 mmHg
and about 40% of patients had one reading of 30 mmHg
or less. The fraction of time during the 24-hour on which
patients remained with DPP below a given cut-off value
is reported in Table 3. During the 24-hour curve, these
patients were exposed to DPP < 50, 40, 30 mmHg for
respectively 3 h 30’ ± 2 h 16’ (range, 30’; 10 h), 1 h 7’ ± 1 h
2’ (0; 5 h 30’), 10’ ± 16’ (0; 1 h 30’), being respectively 13.9 ±
9.0 (range, 1; 40), 4.7 ± 4.1 (0; 22), 1.0 ± 1.2 (0; 6) the num-
ber of time-points at which DPP fell below the given value.
No statistically significant difference was found between the
two study treatments. Thirty-eight percent of low DPP
values were found during office hours (8 am-4 pm), com-
pared to 62% outside office-hours. Twenty-nine percent of
low DPP occurred at night.Discussion
The results of this study show that both IOP and PP can
be very similar in a group of patients treated with bima-
toprost or with LTFC. In fact, with the exception of SBP
and SPP that were higher in the group receiving bimato-
prost, all other comparisons did not show any statisti-
cally significant difference. No major effect of timolol in
lowering PP could be evidenced in this trial. As a second-
ary result, we found that low DPP values were a common
finding in our trial population, despite this sample had a
very well controlled 24-hour IOP. Nearly all cases had at
least one DPP reading below 50 mmHg and 40% below0 <25 <20 <15 <10 <5
DPP
en cut-off values.
Table 3 Exposure time (during a 24-hour period) to DPP
below given cut-off values
DPP cut-off Mean (hours, minutes) sd Range
<50 mmHg 3 h 30’ 2 h 16’ 30’;10 h
<45 mmHg 2 h 6’ 1 h 40’ 0; 8h
<40 mmHg 1 h 7’ 1 h 2’ 0; 5 h 30’
<35 mmHg 26’ 30’ 0; 2 h
<30 mmHg 10’ 16’ 0; 1 h 30’
DPP: diastolic perfusion pressure; sd: standard deviation.
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to a DPP <50 mmHg for more than 3 hours per day.
The effect of timolol on PP is debated. A recent 24-
hour study found that timolol (both solution and gel
formulations) had no relevant effect on BP and PP in
patients with POAG [25]. In another clinical trial where
the timolol add-on therapy in prostaglandin treated glau-
coma patients was evaluated, larger PP fluctuations were
recorded after timolol [26]. In another recent prospective
cross-over study, timolol was found to cause retinal vascu-
lar dysregulation in response to posture change in 30% of
the trial sample after 6 weeks of treatment [27]. In our
trial, timolol did not seem to have a clinically relevant
effect in influencing the 24-hour PP.
A secondary, yet important finding of the present trial,
was the recording of low nocturnal DPP values in a group
of glaucoma patients. The clinical relevance of such a find-
ing is not known but it certainly deserves some discussion.
The role of PP in the pathogenesis (and progression) of
glaucoma is not completely clear, although large epidemi-
ologic studies have shown that ocular PP is a risk factor
for the prevalence, incidence and progression of glaucoma
[28-32]. Data from clinical trials seem to confirm the
importance of PP: in the Early Manifest Glaucoma Trial
(EMGT) [3], patients with low SPP tended to progress
faster, and low SSP was a significant predictor of pro-
gression with an almost 50% higher risk; a recent report
from the “Low-pressure Glaucoma Treatment study”
showed that lower mean ocular perfusion pressure in-
creased the risk for reaching a progression outcome [11].
A high proportion of patients in this trial was exposed
to low PP values for a variable amount of time. It is hard
to tell whether this risk is clinically relevant; unfortu-
nately, the study was not designed with this objective
and the short-term assessment of IOP and PP, the type
of patients included (young and not selected according
to the risk for low PP) are strongly limiting the possibility
of a correct interpretation of our findings. Only long-term
clinical trials assessing both visual field progression and
24-hour circadian IOP and PP in high-risk (e.g. older pa-
tients, patients treated with evening-dosed systemic
anti-hypertensive medications) glaucoma patients will
provide a conclusive answer. Other study limitationsinclude: 1. Holter pressures and IOPs were not re-
corded at the same time; thus, at least potentially, all or
some of the PP values that were derived from Holter
could be wrong. On the other hand, with such study
design Holter readings were not influenced by sudden
awakenings that could not be avoided when IOP was
measured at night and may result in a better estimate of
the “true” pressures occurring during the sleeping period;
2. Patients in the trial were part of a highly selected popu-
lation: they had well controlled IOP values, and, belonging
to a study group, they probably tended to better adhere to
treatment protocol; as a results they were likely to have
better IOPs and PPs than the general glaucoma popula-
tion. This, of course, decreases the generalizability of the
findings; 3. The timing of drugs administration that could
have influenced our findings: in this trial LTFC was ad-
ministered in the morning (as suggested when the study
was planned) while there is now evidence that it can be
more effective when given in the evening [33,34]. The
strengths of this study should be also reported. First, at
least to our knowledge, this is the biggest randomized clin-
ical trial ever carried out with 24-hour circadian IOP and
PP as outcomes in glaucoma patients. Second, the multi-
centre design and the stability of the IOP profile under the
2 study drugs reinforce the validity of our observations.
The vast majority of the evidence about the role of PP in
glaucoma comes from large epidemiologic studies or clin-
ical trials where information on IOP is limited to single or
few observations. It is reasonable to assume that our study
could provide a more accurate estimate of the PPs in a
POAG and OH patient population.
The “true” role of IOP variability and, consequently,
PP in the pathogenesis of POAG and its progression will
remain debated until a reliable tool to assess continuous
IOP (and PP) will be clinically available. It seems we are
not there yet; surrogate methods, as the one we used in
this trial are probably the best options to get an estimate
of short-term IOP variability and PP, though, we are
aware, still far from perfection.
Conclusions
In conclusion, low values of DPP are a common findings
in glaucoma patients, even when IOP is under optimal
control. A significant proportion of such patient can be
exposed to “risky” PP values for a certain amount of
time. The clinical meaning of this finding is still to be
determined.
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